Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss; Sets Stage for 8-week Diabetes and Weight Loss Animal Study
- Lexaria, a global innovator in drug delivery platforms, highlighted results from its DIAB-A22-1 animal study, highlighting a 7% reduction in weight and a 19.9% reduction in blood glucose
- With this success, Lexaria looks to kick off its WEIGHT-A24-1 animal study to examine diabetes and weight loss effects of its patented DehydraTECH(TM)-processed GLP-1 drugs and DehydraTECH-processed CBD
- The study will comprise 12 arms and involve 72 animals. It will run for a total of 12 weeks
- This study will build on previous studies that evidenced DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released highlights from its DIAB-A22-1 animal study on rodents. The study sought to explore the overall efficiency of its patented DehydraTECH(TM)-CBD formulation and its impact on conditions associated with diabetes. This 8-week study resulted in a 7% reduction in weight, as well as a 19.9% reduction in blood glucose, aligning with other study works in animals that pointed to the known anti-inflammatory and antioxidant properties of CBD functioning to lessen some of the essential pathophysiological factors associated with diabetes (https://nnw.fm/NgVyV ).
With the success of this study, Lexaria looks to kick off its WEIGHT-A24-1 animal study that will seek to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1”) drugs and DehydraTECH-processed cannabidiol alone and in combination. This study will be executed by a Health Canada-licensed Canadian research laboratory and is set to commence within 45 days (https://nnw.fm/fXfCd ).
This study will comprise 12 arms, 8 of which composition manufacturing has already been completed. Each arm is expected to be dosed for twelve weeks following an acclimation period, during which over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for the purposes of detailed pharmacokinetic drug delivery analyses. The remaining study arms, 9 through 12, will kick off later due to some information outputs required from the other study arms.
With WEIGHT-A24-1, Lexaria looks to build on the success of its previous studies, including the goal of evidencing DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue. Industry studies have evidenced that small peptide GLP-1R agonists activate a subset of GLP-1R-expressing neurons in the arcuate nucleus involved in weight loss (https://nnw.fm/WlLPZ ). Having expressed its resolve to focus on GLP-1 studies for the 2024 calendar year, the WEIGHT-A24-1 study is one of several planned for 2024.
It highlights the company’s commitment to its course and creating shareholder value. It also reflects its commitment to further developing its DehydraTECH technology and opening it up to more areas of application that offer value to individuals and companies alike. As Lexaria looks to embark on three human studies this year, including a 12-week chronic dosing human study as well as long-term stability testing, WEIGHT-A24-1 will play an integral role in shaping their outcome and affirming the overall effectiveness of its DehydraTECH technology.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria, a global innovator in drug delivery platforms, highlighted results from its DIAB-A22-1 animal study, highlighting a 7% reduction in weight and a 19.9% reduction in blood glucose
- With this success, Lexaria looks to kick off its WEIGHT-A24-1 animal study to examine diabetes and weight loss effects of its patented DehydraTECH(TM)-processed GLP-1 drugs and DehydraTECH-processed CBD
- The study will comprise 12 arms and involve 72 animals. It will run for a total of 12 weeks
- This study will build on previous studies that evidenced DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released highlights from its DIAB-A22-1 animal study on rodents. The study sought to explore the overall efficiency of its patented DehydraTECH(TM)-CBD formulation and its impact on conditions associated with diabetes. This 8-week study resulted in a 7% reduction in weight, as well as a 19.9% reduction in blood glucose, aligning with other study works in animals that pointed to the known anti-inflammatory and antioxidant properties of CBD functioning to lessen some of the essential pathophysiological factors associated with diabetes (https://nnw.fm/NgVyV ).
With the success of this study, Lexaria looks to kick off its WEIGHT-A24-1 animal study that will seek to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1”) drugs and DehydraTECH-processed cannabidiol alone and in combination. This study will be executed by a Health Canada-licensed Canadian research laboratory and is set to commence within 45 days (https://nnw.fm/fXfCd ).
This study will comprise 12 arms, 8 of which composition manufacturing has already been completed. Each arm is expected to be dosed for twelve weeks following an acclimation period, during which over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for the purposes of detailed pharmacokinetic drug delivery analyses. The remaining study arms, 9 through 12, will kick off later due to some information outputs required from the other study arms.
With WEIGHT-A24-1, Lexaria looks to build on the success of its previous studies, including the goal of evidencing DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue. Industry studies have evidenced that small peptide GLP-1R agonists activate a subset of GLP-1R-expressing neurons in the arcuate nucleus involved in weight loss (https://nnw.fm/WlLPZ ). Having expressed its resolve to focus on GLP-1 studies for the 2024 calendar year, the WEIGHT-A24-1 study is one of several planned for 2024.
It highlights the company’s commitment to its course and creating shareholder value. It also reflects its commitment to further developing its DehydraTECH technology and opening it up to more areas of application that offer value to individuals and companies alike. As Lexaria looks to embark on three human studies this year, including a 12-week chronic dosing human study as well as long-term stability testing, WEIGHT-A24-1 will play an integral role in shaping their outcome and affirming the overall effectiveness of its DehydraTECH technology.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
